Mineralys Therapeutics Successfully Priced Public Offering
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a leading clinical-stage biopharmaceutical company focused on pioneering treatments for various health conditions, has made an exciting announcement. The company has priced an underwritten public offering of 12,962,962 shares of its common stock, set at a public offering price of $13.50 per share. This strategic move is expected to generate about $175.0 million in gross proceeds for Mineralys, prior to any underwriting discounts, commissions, or additional estimated expenses related to the offering.
Detailing the Offering Process
The financing will enable the company to continue its vital work targeting issues such as hypertension, chronic kidney disease (CKD), and obstructive sleep apnea (OSA). An interesting aspect of this offering is the 30-day option granted to underwriters, allowing them to purchase up to an additional 1,944,444 shares, offering further capital flexibility for the company.
Support from Major Financial Institutions
A number of prominent financial institutions are participating in this public offering as joint book-running managers, including BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel, and Wells Fargo Securities. Additionally, LifeSci Capital is serving as the lead manager, with H.C. Wainwright & Co. taking on the role of co-manager for this significant financial event.
Funding Clinical Development and Growth
The primary aim for the proceeds realized from this public offering is to support the clinical development of lorundrostat, the company’s innovative treatment aimed at addressing conditions linked to dysregulated aldosterone. The funds will be allocated towards research and development, manufacturing efforts, and pre-commercialization activities. Beyond these purposes, a portion of the proceeds is also earmarked for general corporate needs and working capital.
Transparency Through Regulatory Compliance
The offering is compliant with an established shelf registration statement that has already been declared effective by the Securities and Exchange Commission (SEC). Mineralys has promptly filed a preliminary prospectus supplement and will also file a final version as part of the offering process, further ensuring that all necessary regulatory guidelines are met.
About Mineralys Therapeutics
Founded with the mission to create advanced treatment options, Mineralys Therapeutics specializes in therapies intended for conditions such as hypertension, CKD, and OSA. The company's innovative product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. This groundbreaking treatment targets cardiorenal conditions associated with dysregulated aldosterone levels, emphasizing the company’s commitment to improving patient health and quality of life.
Connection to Investor Relations
Mineralys Therapeutics is dedicated to maintaining open communication with investors. For any inquiries related to this public offering or other corporate information, stakeholders can reach out through the following contact:
Investor Relations Email: investorrelations@mineralystx.com
Frequently Asked Questions
What is the purpose of the public offering?
The public offering aims to raise capital to fund clinical development efforts for lorundrostat, along with general corporate expenses.
Who are the underwriters for this offering?
The offering is being handled by major financial entities, including BofA Securities, Evercore ISI, Goldman Sachs, Stifel, and Wells Fargo Securities.
When is the offering expected to close?
The offering is projected to close shortly after the fulfillment of customary closing conditions.
What will the funds from the public offering be used for?
The funds will primarily be allocated towards the clinical development of lorundrostat, research, manufacturing, and other essential corporate activities.
What makes lorundrostat unique?
Lorundrostat is a highly selective aldosterone synthase inhibitor that targets conditions affected by dysregulated aldosterone, offering a novel approach to managing hypertension and related disorders.
